Literature DB >> 8387963

Rufloxacin once daily versus ofloxacin twice daily for treatment of complicated cystitis and upper urinary tract infections. Italian Multicentre UTI Rufloxacin Group.

R Mattina1, C E Cocuzza, M Cesana.   

Abstract

The efficacy and safety of rufloxacin once daily was compared with that of ofloxacin b.i.d. for therapy of complicated cystitis and upper urinary tract infections. Eighty-three patients were randomly assigned to receive rufloxacin as a loading dose of 400 mg on the first day, followed by 200 mg s.i.d., and 80 received ofloxacin 300 mg b.i.d. Both agents were administered orally for a median duration of eight days. Bacterial elimination rates after treatment were 90% for rufloxacin and 81% for ofloxacin. Half of the treatment failures occurred in patients with infections caused by uropathogens that became either less sensitive or resistant to the quinolones being studied. At a two-week follow-up, recurrences had not occurred in any of the rufloxacin patients and had occurred in 17% of the ofloxacin patients. Minor adverse reactions were reported by 12 and 13 patients, respectively. Rufloxacin once daily is as effective as ofloxacin b.i.d. for the treatment of complicated cystitis and upper urinary tract infections.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387963     DOI: 10.1007/bf01710743

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  26 in total

Review 1.  The Garrod lecture. Progress in understanding urinary infections.

Authors:  W Brumfitt
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

2.  Double-blind, dose-range-finding study of fleroxacin (RO 23-6240; AM-833) for treatment of complicated urinary tract infections.

Authors:  M J Wolfhagen; A I Hoepelman; J Verhoef
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

3.  Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.

Authors:  R Wise; J Johnson; N O'Sullivan; J M Andrews; B P Imbimbo
Journal:  J Antimicrob Chemother       Date:  1991-12       Impact factor: 5.790

4.  Ofloxacin in urinary tract infections.

Authors:  B Kromann-Andersen; K Krøyer Nielsen
Journal:  Scand J Infect Dis Suppl       Date:  1990

5.  Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.

Authors:  B P Imbimbo; G Broccali; M Cesana; F Crema; G Attardo-Parrinello
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Widespread quinolone resistance among methicillin-resistant Staphylococcus aureus isolates in a general hospital.

Authors:  I Shalit; S A Berger; A Gorea; H Frimerman
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

7.  Comparative study using norfloxacin and amoxycillin in the treatment of complicated urinary tract infections in geriatric patients.

Authors:  D A Leigh; E C Smith; J Marriner
Journal:  J Antimicrob Chemother       Date:  1984-05       Impact factor: 5.790

8.  Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.

Authors:  J C Kisicki; R S Griess; C L Ott; G M Cohen; R J McCormack; W M Troetel; B P Imbimbo
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

9.  Norfloxacin treatment in complicated urinary tract infection.

Authors:  J B Boerema; H K van Saene
Journal:  Scand J Infect Dis Suppl       Date:  1986

Review 10.  Fluoroquinolone antimicrobial agents.

Authors:  J S Wolfson; D C Hooper
Journal:  Clin Microbiol Rev       Date:  1989-10       Impact factor: 26.132

View more
  5 in total

1.  In vitro antimycoplasmal activities of rufloxacin and its metabolite MF 922.

Authors:  P M Furneri; G Bisignano; G Cerniglia; G Nicoletti; M Cesana; G Tempera
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

Review 2.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

3.  Randomized, double-blind comparison of single-dose regimens of rufloxacin and pefloxacin for acute uncomplicated cystitis in women. French Multicenter Urinary Tract Infection-Rufloxacin Group.

Authors:  A Jardin; M Cesana
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

4.  Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: clinical evaluation and pharmacodynamic considerations.

Authors:  G Del Río; F Dalet; L Aguilar; J Caffaratti; R Dal-Ré
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Effects of magnesium-aluminum hydroxide antacid on absorption of rufloxacin.

Authors:  M Lazzaroni; B P Imbimbo; S Bargiggia; O Sangaletti; L Dal Bo; G Broccali; G Bianchi Porro
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.